(Q38027909)

27 August 2017

title

Review article: overlap syndromes and autoimmune liver disease (English)

1 reference

27 August 2017

1 reference

Gideon M. Hirschfield

series ordinal

2

1 reference

27 August 2017

P J Trivedi

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

22 July 2012

1 reference

Alimentary Pharmacology & Therapeutics

27 August 2017

published in

1 reference

27 August 2017

volume

36

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

517-533

1 reference

Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Gene dosage--limiting role of Aire in thymic expression, clonal deletion, and organ-specific autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Genetics of liver disease: immunogenetics and disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Autoimmune hepatitis, HLA and extended haplotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Autoimmune hepatitis triggered by hepatitis A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Drug-induced autoimmune-like hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Progress in the genetics of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Genetics in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Disease-specific autoantibodies in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Cryptogenic chronic hepatitis and its changing guise in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Primary sclerosing cholangitis: epidemiology, natural history, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Autoantibodies in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Autoantibodies and liver disease: uses and abuses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Diagnosis and treatment of autoimmune hepatitis at age 65 and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Autoimmune hepatitis in childhood: a 20-year experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Autoimmune acute liver failure: proposed clinical and histological criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Concurrent autoimmune diseases in patients with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Simplified criteria for the diagnosis of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

PSC, AIH and overlap syndrome in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Autoimmune hepatitis with incidental histologic features of bile duct injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Overlap syndromes among autoimmune liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Autoimmune overlap syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Development of autoimmune hepatitis in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Performance parameters of the diagnostic scoring systems for autoimmune hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Diagnosis and management of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Autoimmune hepatitis in Italy: the Bologna experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Long-Term Effect of Corticosteroid Treatment in Primary Sclerosing Cholangitis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Diagnosis and management of primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Budesonide induces complete remission in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

The use of budesonide in the treatment of autoimmune hepatitis in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Mycophenolate mofetil as second line therapy in autoimmune hepatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Short-term cyclosporine induces a remission of autoimmune hepatitis in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05223.X

10.1111/J.1365-2036.2012.05223.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference